Effectiveness and Tolerability of Trimetazidine 80mg Once Daily in Patients With Chronic Coronary Syndrome: The V-GOOD Study

Patients must be informed about their participation in this study and the transfer of their clinical data outside the research center to statistical data analysts. The patient consent form must be obtained in writing. Patients diagnosed with chronic coronary syndrome and persistent stable angina, for whom the cardiologist chose to prescribe Trimetazidine 80mg once daily, were included in the study. Clinical information was collected in three distinct visits at baseline (V1), 1 month (V2), and 3 months (V3). During these visits, cardiologists collected the following variables based on a weekly occurrence: number of angina crises, short-acting nitrates (SAN) consumption, Canadian Cardiovascular Society (CCS) classification, level of self-reported daily physical activity, adherence, and tolerability to the treatment. Physical activity was measured using a scale from 1 to 10 (1 = no limitations, 5 = moderate limitations, and 10 = very marked limitations). Adherence was assessed by a previously validated six-item questionnaire. Assessment of therapy efficacy and tolerability were rated by the physician as "very satisfactory", "satisfactory", "not sufficiently satisfactory", and "unsatisfactory".

Inclusion criteria

• Patients with confirmed Chronic Coronary Syndrome and persistent stable angina;
• Patients who are going to start using Vastarel Caps LP® as per their doctor's recommendation.

Exclusion criteria

• Hypersensitivity to the active ingredient or any of the excipients listed in Vastarel Caps LP®;
• Parkinson's disease, Parkinson's symptoms, tremors, restless leg syndrome, and other related movement disorders;
• Severe renal impairment (creatinine clearance <30 mL/min);
• Moderate renal impairment (creatinine clearance [30-60] mL/min).